Bruker Corporation (Nasdaq: BRKR), a provider of life science and diagnostics systems and solutions, announced on Monday that it has introduced a USD100 high-fidelity plasma proteomics solution using PreOmics ENRICH and timsTOF HT.

This method enables deep, unbiased plasma proteomics at scale, delivering 99% specificity at 1% false discovery rate (FDR), crucial for large-scale studies in biopharma.

Biognosys is also offering services using its P2 enrichment and Spectronaut 19, allowing identification of up to 9,000 proteins. These offerings include integration with Alamar Bio's ultra-high sensitivity NULISA panels for inflammation and CNS multiplex analysis.

Bruker's glyco-PASEF and timsTOF Ultra 2 enable high-sensitivity glycoproteomics, with a twofold increase in glycopeptide identifications. Enhanced by machine learning, TIMSrescore technology improves peptide identification for post-translational modifications (PTMs) and metaproteomics, ensuring 99.9% specificity at 0.1% FDR.

The company also announced its 4D-Multiomics platform, integrating proteomics, lipidomics and metabolomics insights via ProteoScape, facilitating multi-dimensional analysis for deeper biological understanding.